Company intelligence / Profile preview

Varian Bioscience

Jupiter, Florida, United States

Ownership: Private
Development stage: Other

Overview

Varian Bio is a precision oncology company focused on developing novel small molecule therapeutics that target the Hepatocyte Nuclear Factor 4 alpha (HNF4A) transcription factor. HNF4A is a master regulator of gene expression in the liver and gastrointestinal tract, and its dysregulation is implicated in the progression of various cancers, particularly colorectal cancer. The company's lead program aims to inhibit HNF4A to disrupt the transcriptional networks that drive tumor growth and survival. By targeting this previously "undruggable" transcription factor, Varian Bio seeks to provide new treatment options for patients with gastrointestinal malignancies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Varian Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Varian Bioscience.

Explore the full profile